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(57) ABSTRACT 
The invention provides highly functionalised spiro-fused 
aZetidinones having a cycloheXane moiety With the desired 
number of protected or unprotected hydroXyl groups Which 
are introduced With high stereo and regioselectivity, as Well 
as processes for obtaining the compounds. 
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REGIOSELECTIVE HYDROXYLATION, 
FUNCTIONALISATION AND PROTECTION OF 
SPIROLACTAMS 
FIELD OF THE INVENTION 
[0001] The present invention relates to neW regioselec 
tively hydroXylated, protected and functionaliZed spirolac 
tams and to processes for their synthesis. 
BACKGROUND OF TH INVENTION 
[0002] Lactams are compounds of high interest due to 
their biological activities, for example Well knoWn [3-lac 
tams such as some penicillins, cephalosporins and carbap 
enems have antibacterial activity. 
[0003] Spirolactams are one particular class of lactams 
that have shoWn interesting biological properties. Some 
spiro-fused aZetidinones have been described as having 
antibacterial activity, see US. Pat. No. 4,680,388, or hypo 
cholesterolemic properties, see for eXample W0 94 17038. 
Additionally, if these compounds have adequate functional 
ity, they are valuable intermediates toWards different fami 
lies of compounds. The spirolactam ring is the equivalent of 
an alpha amino or hydroXy aminoacid and opens many 
possibilities in diastero and/or enantioselective synthesis. 
[0004] MiyaZaWa, E. et al. in Heterocycles, vol 59, 1:149 
160 “Synthesis of spiro-fused nitrogen heterocyclic com 
pounds via N-methoXy-N-acylnitrenium ions using phe 
nyliodine (III) bis(tri?uoroacetate) in tri?uoroethanol” 
describe a process to obtain functionalised spirolactams 
including some spirodienones. 
[0005] KukugaWa, Y. e al. in J. Org. Chem. 2003, vol. 68, 
6739-6744 “Intramolecular cycliZation With nitrenium ions 
generated by treatment of N-acylaminophthalimides With 
hypervalent iodine compounds: formation of lactams and 
spirofused lactams” describes the formation of functiona 
lised spirolactams having diene and dienone funcionalities. 
[0006] The conduritols, aminoconduritols, aminoinositols 
and their derivatives also possess interesting biological 
properties, some of them have been shoWn as being antitu 
moral and antibiotic. Although some synthetic processes 
eXist for these compounds (See Yong-Uk KWon et al, J. Org. 
Chem. 2002, V1. 67, 3327-3338 “Facile syntheses of all 
possible diastereomers of conduritol and various derivatives 
of inositol stereoisomers in high enantiopurity from myo 
inositol”), there are still difficulties to obtain these com 
pounds or corresponding analogues. 
[0007] As it is apparent from the above, any ef?cient 
process for producing functionalised spirolactam com 
pounds in high yield, With various functionalities, intro 
duced in a controlled and regioselective manner, Would be a 
Welcome contribution to the art and Will open the door to a 
variety of biologically active compounds. 
SUMMARY OF THE INVENTION 
[0008] Starting from the compounds described in our 
application EP 04380104.2, We found a basic set of pro 
cesses that alloWs the controlled synthesis of very stable, 
highly functionalised, spiro-fused aZetidinones Which are 
useful as intermediate compounds in the preparation of a 
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variety of chemical structures, including, if necessary, by 
means of chemo-, loco-, regio-, diastero- and/or enantiose 
lective processes. 
[0009] In one aspect the invention provides a compound of 
formula I: 
formula I 
R5 R6 
R3 R2 
R4 R1 
Z N W 
Y \Y/ 
O 
[0010] Wherein R1, R2, R3, R4 are each independently 
selected from H, OH or OPr; 
[0011] R5 and R6 together are :0 or R5 is selected from 
H, OH, OPr and R6 is selected from hydrogen, cyano, 
substituted or unsubstituted alkyl, substituted or unsub 
stituted cycloalkyl, substituted or unsubstituted alk 
enyl, substituted or unsubstituted alkynyl, substituted 
or unsubstituted aryl, substituted or unsubstituted het 
erocyclyl, With the proviso that at least one of R1, R2, 
R3, R4 or R5 is OH or OPr; 
[0012] Pr is an hydroXyl protecting group Which can be 
the same or different on each of R1, R2, R3, R4 or R5; 
[0013] the dotted line represents a single or double 
bond, With the proviso that When both R1 and R2 or R3 
and R4 are H then there is a double bond betWeen the 
tWo C to Which the H are linked; 
[0014] Z is —(CRaRb)n— Wherein n is a number 
selected from 1, 2, 3 and Ra and Rb are each indepen 
dently selected from hydrogen, substituted or unsub 
stituted alkyl, substituted or unsubstituted cycloalkyl, 
substituted or unsubstituted alkenyl, substituted or 
unsubstituted aryl, substituted or unsubstituted hetero 
cyclyl, substituted or unsubstituted alkoXy, substituted 
or unsubstituted aryloXy, substituted or unsubstituted 
amino or halogen; 
[0015] Y is selected from —O—, —S—, —N(RaRb)— 
or —C(O)—, Wherein Ra and Rb are as previously 
de?ned and do not form a cyclic ring; 
[0016] W is a group selected from substituted or unsub 
stituted arylalkyl, substituted or unsubstituted hetero 
cyclylalkyl, substituted or unsubstituted alkenyl; 
[0017] or a salt, complex or solvate thereof. 
[0018] In one embodiment We prefer that n is 1. In this 
case Z is preferably —CH2—. In another embodiment W is 
arylalkyl, preferably benZyl. In a further embodiment Y is 
preferably —O—. 
[0019] The invention also provides for a process for the 
preparation of a compound according of formula I, Which 
comprises in any order one or more steps selected from the 
group consisting of: 
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[0020] a) hydroXylation or dihydroXylation 
[0021] b) hydroXyl or carbonyl protection 
[0022] c) nucleophilic attack at the carbonyl group 
[0023] d) hydroXyl inversion 
[0024] applied to a compound of formula IV: 
formula IV 
0 
Z N W 
Y \Y/ 
O 
[0025] Wherein Z, Y and W are as de?ned above. 
DETAILED DESCRIPTION OF THE 
INVENTION 
[0026] The invention provides compounds of formula I as 
above de?ned. In the compounds of formula I, the group Z 
gives rise to a ring of 4, 5 or 6 members. Substitution on 
position Z creates a stereogenic center that could induce 
selective functionalisation on the benZodienone moiety. In a 
preferred embodiment Z is —CH2)n—. Although rings of 5 
or 6 are also comprised Within the scope of the invention, in 
one embodiment the [3-lactam ring (n=1) is preferred 
because of the further uses that can be given to such 
compounds. 
[0027] The group Y in the compounds of formula I plays 
a role in the stability and conformation. In an embodiment 
Y is preferably —O—, although other atoms are not 
eXcluded as long as the ?nal product is stable. 
[0028] As We already mentioned the W group is important 
for the stabiliZation of the compound of formula I. Prefer 
ably it comprises unsaturated bonds or aromatic groups to 
increase the at interaction. Aralkyl groups and alkenyl groups 
are preferred since they give the best stability. In a particular 
embodiment, W is —CRaRb-Q or —SiRaRb-Q since the 
stability of the conformation is further improved by the 
presence of a —CRaRb— or a —SiRaRb— linker betWeen 
Y and the substituent Q Which has at interactions With 
the benZodienone moiety. The linker is preferably 
—CHRa—. In this case a stereogenic center is introduced 
Which alloWs for the selectivity or speci?city of any further 
reaction, distinguishing the tWo double bonds of the benZo 
dienone. This Will advantageously open the Way to diastero 
and/or enantioselective synthesis in addition to the selection 
for one face Which is explained beloW. Depending on the 
siZe of Ra it can also modulate the at interactions. 
[0029] In one embodiment W is an aralkyl group. Among 
the aryl groups susbtituted or unsubstituted phenyl and 
naphthyl are preferred. Heterocyclylalkyl groups are also 
envisaged. Phenyl is the simplest subtituent and gives good 
results. 
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[0030] In the above de?nition of compounds of formula (I) 
and in the description the folloWing terms have the meaning 
indicated: 
[0031] “Alkyl” refers to a straight or branched hydrocar 
bon chain radical consisting of carbon and hydrogen atoms, 
containing no saturation, having one to eight carbon atoms, 
and Which is attached to the rest of the molecule by a single 
bond, e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, 
n-pentyl, etc. Alkyl radicals may be optionally substituted by 
one or more substituents independently selected from the 
group consisting of a halo, hydroXy, alkoXy, carboXy, cyano, 
carbonyl, acyl, alkoXycarbonyl, amino, nitro, mercapto and 
alkylthio. 
[0032] “AlkoXy” refers to a radical of the formula —ORa 
Where Ra is an alkyl radical as de?ned above, e.g., methoXy, 
ethoXy, propoXy, etc. “AryloXy” refers to a radical of for 
mula —ORb Wherein Rb is an aryl radical as de?ned beloW. 
[0033] “Amino” refers to a radical of the formula —NH2, 
—NHRa, —NRaRb. 
[0034] “Aryl” refers to a phenyl, naphthyl or anthracyl 
radical. The aryl radical may be optionally substituted by 
one or more substituents selected from the group consisting 
of hydroXy, mercapto, halo, alkyl, phenyl, alkoXy, haloalkyl, 
nitro, cyano, dialkylamino, aminoalkyl, acyl and alkoXycar 
bonyl, as de?ned herein. 
[0035] “Aralkyl” refers to an aryl group linked to an alkyl 
group such as benZyl and phenethyl. 
[0036] “Cycloalkyl” refers to a saturated carbocyclic ring 
having from 3 to 8 carbon atoms. 
[0037] “Heterocycle” refers to a heterocyclyl radical. The 
heterocycle refers to a stable 3- to 15-membered ring Which 
consists of carbon atoms and from one to ?ve heteroatoms 
selected from the group consisting of nitrogen, oXygen, and 
sulfur, preferably a 4- to 8-membered ring With one or more 
heteroatoms, more preferably a 5- or 6-membered ring With 
one or more heteroatoms. For the purposes of this invention, 
the heterocycle may be a monocyclic, bicyclic or tricyclic 
ring system, Which may include fused ring systems; and the 
nitrogen, carbon or sulfur atoms in the heterocyclyl radical 
may be optionally oxidised; the nitrogen atom may be 
optionally quaterniZed; and the heterocyclyl radical may be 
partially or fully saturated or aromatic. EXamples of such 
heterocycles include, but are not limited to, aZepines, ben 
ZimidaZole, benZothiaZole, furan, isothiaZole, imidaZole, 
indole, piperidine, piperaZine, purine, quinoline, thiadiaZole, 
tetrahydrofuran. 
[0038] “HydroXyl protecting group” refers to a group that 
blocks the OH function for further reactions. The hydroXyl 
protecting groups are Well knoWn in the art, representative 
protecting groups are silyl ethers such as trimethylsilyl ether, 
triethylsilyl ether, tert-butyldimethylsilyl ether, tert-butyl 
diphenylsilyl ether, tri-isopropylsilyl ether, diethylisopro 
pylsilyl ether, theXyldimethylsilyl ether, triphenylsilyl ether, 
di-tert-butylmethylsilyl ether; alkyl ethers such as methyl 
ether, tert-butyl ether, benZyl ether, p-methoXybenZyl ether, 
3,4-dimethoXybenZyl ether, trityl ether; allyl ether; 
alkoXymethyl ether such as methoXymethyl ether, 2-meth 
oXyethoXymethyl ether, benZyloXymethyl ether, p-methoXy 
benZyloXymethyl ether, 2-(trimethylsilyl)ethoXymethyl 
ether; tetrahydropyranyl and related ethers; methylthiom 
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ethyl ether; Esters such as acetate ester, benZoate ester; 
pivalate ester; methoxyacetate ester; chloroacetate ester; 
levulinate ester; Carbonates such as benZyl carbonate, p-ni 
trobenZyl carbonate, tert-butyl carbonate, 2,2,2-trichloroet 
hyl carbonate, 2-(trimethylsilyl)ethyl carbonate, allyl car 
bonate. Additional examples of hydroxyl protecting groups 
can be found in reference books such as Greene and Wuts’ 
“Protective Groups in Organic Synthesis”, John Wiley & 
Sons, Inc., NeW York, 1999. 
[0039] References herein to substituted groups in the 
compounds of the present invention refer to the speci?ed 
moiety that may be substituted at one or more available 
positions by one or more suitable groups, e.g., halogen such 
as ?uoro, chloro, bromo and iodo; cyano; hydroxyl; nitro; 
aZido; alkanoyl such as a C1-6 alkanoyl group such as acyl 
and the like; carboxamido; alkyl groups including those 
groups having 1 to about 12 carbon atoms or from 1 to about 
6 carbon atoms and more preferably 1-3 carbon atoms; 
alkenyl and alkynyl groups including groups having one or 
more unsaturated linkages and from 2 to about 12 carbon or 
from 2 to about 6 carbon atoms; alkoxy groups having one 
or more oxygen linkages and from 1 to about 12 carbon 
atoms or 1 to about 6 carbon atoms; aryloxy such as 
phenoxy; alkylthio groups including those moieties having 
one or more thioether linkages and from 1 to about 12 
carbon atoms or from 1 to about 6 carbon atoms; alkylsul? 
nyl groups including those moieties having one or more 
sul?nyl linkages and from 1 to about 12 carbon atoms or 
from 1 to about 6 carbon atoms; alkylsulfonyl groups 
including those moieties having one or more sulfonyl link 
ages and from 1 to about 12 carbon atoms or from 1 to about 
6 carbon atoms; aminoalkyl groups such as groups having 
one or more N atoms and from 1 to about 12 carbon atoms 
or from 1 to about 6 carbon atoms; carbocylic aryl having 6 
or more carbons, particularly phenyl or naphthyl and aralkyl 
such as benZyl. Unless otherWise indicated, an optionally 
substituted group may have a substituent at each substitut 
able position of the group, and each substitution is indepen 
dent of the other. 
[0040] In our copending application, EP04380104.2, 
Which is incorporated herein by reference in its entirety, We 
describe neW compounds having a formula IV and processes 
for their obtention: 
formula IV 
0 
Z N W \ / 
Y Y 
O 
[0041] Wherein Z is —CRaRb)n— Wherein n is a number 
selected from 1, 2, 3 and Ra and Rb are each independently 
selected from hydrogen, substituted or unsubstituted alkyl, 
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substituted or unsubstituted cycloalkyl, substituted or unsub 
stituted alkenyl, substituted or unsubstituted aryl, substituted 
or unsubstituted heterocyclyl, substituted or unsubstituted 
alkoxy, substituted or unsubstituted aryloxy, substituted or 
unsubstituted amino, or halogen; 
[0042] Y is selected from —, —S—, —N(RaRb)— or 
—C(O)—, Wherein Ra and Rb are as previously 
de?ned and do not form a cyclic ring; 
[0043] and W is a group With suf?cient electronic density 
to stabiliZe the compound through at interactions With 
the benZodienone moiety, preferably a group having unsat 
urated bonds or aromatic groups, more preferably it is 
selected from substituted or unsubstituted arylalkyl, substi 
tuted or unsubstituted heterocyclylalkyl, substituted or 
unsubstituted alkenyl. 
[0044] These compounds are remarkably stable due to n 
interactions betWeen the W group and the benZodienone 
moiety. Additionally these compounds adopt a preferential 
conformation in Which the W group blocks one of the faces 
of the benZodienone (hereinafter the [3 face) and is “?xed” 
there by the at interactions, directing further reactions to the 
free face of the benZodienone moeity (hereinafter the ot 
face). 
[0045] Taking advantage of this, We have noW found that 
starting from these compounds it is possible to regioselec 
tively hydroxylate, functionalise and protect the different 
positions of the benZodienone group, to give a broad range 
of stable compounds having the desired functionality and 
protection at each of the 5 available positions. These highly 
functionalised compounds are useful as building blocks for 
a Wide variety of bioactive compounds. 
[0046] If only one hydroxy group is desired, it can be 
introduced regioselectively for example via formation of the 
cyanhydrine on the carbonyl group, the hydroboration or 
hydrosililation of one of the double bonds (via the a face), 
then oxidation and ?nal treatment With acid or AgF: 
TMSCN 
—> 
O 
1. BH3 
4> 
2. oxid OH 
3. H’r AgF 
’ Z N W 
Y \Y/ 
O 
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[0047] Other alternatives procedures are possible. Signi? 
cantly, the hydroxylation takes place via one face of the 
dienone only. The hydroxyl group can then be protected With 
any desired hydroxyl protecting group such as those listed 
above. 
[0048] In another embodiment of the invention We provide 
for the diastereoselective dihydroxylation of one of the 
double bonds of the benZodienone moiety. This is a surpris 
ing result, in vieW of the expected poor reactivity of the 
structure of formula IV, due to the highly deactivated double 
bonds. Additionally, contrary to What is expected, the dihy 
droxylation takes place regioselectively, only via the ot face: 
0 0 
OH 
OH 
Z N Z N\ /W 
Y Y Y 
o o 
[0049] This oxidation occurs readily under mild condi 
tions, such as using OsO4 in a polar solvent, for example a 
mixture of Water an ketone, in the presence of an amine such 
as N-methylmorpholine N-oxide. Alternative oxidation sys 
tems Will be readily apparent to the person skilled in the are 
and can be found in standard references for organic synthesis 
such as Noyori, R. “Asymmetric catalysis in organic syn 
thesis”, John Wiley and Sons, Inc. (1994) or Ojima, I. 
“Catalytic asymmetric synthesis VCH, (1993) 
[0050] In another aspect of the invention We have found 
that the dihydroxylated compound can be selectively pro 
tected. Indeed, When carrying out a protection such as With 
C-TBDMS We found that the hydroxyl at position 2 reacted 
until being completely protected, and only then the OH at 
position 1 is protected. 
O O 
OH OPr 
—> 
OH OH 
ZYN\Y/W ZYN\Y/W 
O O 
[0051] Without being bound by theory We believe that this 
is due to the existence of C—H at interactions betWeen the 
H at position 2 and the W group. This means that the —OH 
at position 2 is in an equatorial conformation, more reactive, 
While the —OH at position 1 is in an axial conformation, less 
reactive. This alloWs the selective reaction of one position 
With respect to the other. 
—> 
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[0052] Therefore, both the facial selection (0. versus [3) 
When carrying out the hydroxylation, and the different 
reactivity of positions 1 and 2, due to the particular confor 
mations generated by the presence of the W group and its 
interactions With the rest of the molecule, alloWs for a ?ne 
tuned control of the functionalisation of the molecule. 
[0053] The tWo hydroxy groups can be protected With the 
same protecting group as explained above, or With different 
protecting groups, ?rst protecting the position 2 and then the 
position 1: 
O O 
OPrl OPrl 
Pr2 
—> 
OH OPrZ 
Z N W Z N W \ / 
Y Y Y \Y/ 
O O 
[0054] To introduce the hydroxyl protecting groups stan 
dard procedures can be used, such as those described in 
Greene and Wuts’ “Protective Groups in Organic Synthe 
sis”, John Wiley & Sons, Inc., NeW York, 1999 or Kocienski, 
P. J. “Protecting Groups”, 3rd Ed. Thieme Chemistry, 2003. 
[0055] In another embodiment the carbonyl group can also 
be selectively functionaliZed for example by Nucleophilic 
addition. Importantly, the lactam group does not react 
instead because it has a Weinreb type of amide. Thus 
cyanides, organolithium compounds, Grignard’s reagents, 
ketones among other can be easily added to introduce the 
desired functionality at this position. If an hydride is used 
then an hydroxy at position 3 is generated. Suitable proce 
dures for this kind of reactions are knoWn in the art and can 
be found for example in Fischer, A. et al J. Org. Chem, 1987, 
52, 4464-4468 “Formation of 4-nitrocyclohexa-2,5-dienols 
by addition of organolithium reagents to 4-alkyl-4-nitrocy 
clohexa-2,5-dione”; Wipf et al.,Angew. Chem. Int. Ed. Engl. 
1997, 36, no. 7, 764-767; Fischer, A. et al., Tetrahedron letL, 
1980, 21, 701-704; Carreno, M. et al.,]. Org. Chem, 1997, 
62, 26, 9128-9137. 
[0056] The additions can be done independently of the 
functionalisation of the other positions. If no other hydroxy 
groups are present: 
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0 
TMSCN 
—> 
Z N W 
Y \Y/ 
O 
TMSQ CN TMSO \CN 
+ 
Z N W Z N W \ / \ / 
Y Y Y Y 
O O 
[0057] This reaction occurs With no stereoselectivity. The 
compounds can be in any case separated by resolution 
procedures knoW in the art, such as chromatography. 
[0058] As an alternative to functionalisation, if desired the 
carbonyl group can be protected using knoW carbonyl pro 
tecting groups. 
[0059] We have found that When the compound of formula 
IV is ?rst dihydroxylated and then the addition to the 
carbonyl is carried out, complete stereoselectivity is 
achieved. Although not completely clear, it appears that this 
important stereoselectivity is due to stereoelectronic effects 
betWeen positions 2 and 3, and to the above mentioned 
conformation at position 2. For example: 
0 PrZQ CN 
oPr1 " OPr1 
PrZCN 
—> 
OH oPr2 
Z N W Z N W \ / 
T Y \Y/ 
O 
[0060] In this case the addition and the protection of the 
second hydroxyl group are carried out at the same time. 
Alternatively, only addition can take place. 
[0061] In another aspect of the invention, the second 
double bond (positions 4 and 5) can also be stereoselectively 
hydroxylated. This occurs more readily When the carbonyl 
group at position 3 is present, We think because it alloWs the 
in situ generation of an allylic alcohol, Which might indicate 
that it plays a role in the oxidation process. Thus, under mild 
conditions: 
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O O 
OPrl H00,’ OPr1 
OSO4 
—> ‘u. 
OH Ho‘“ OH 
Z N W Z N W 
Y \Y/ Y \Y/ 
O O 
[0062] In this case the hydroxyl groups appear at the 0 
face, We believe for stereoelectronic reasons. If a different 
stereochemistry is desired the appropriate oxidation or 
epimeriZation conditions can be selected. For example, 
under selective acidic or basic conditions the hydroxy at 
position 4 epimeriZes. Alternatively hydroxyl inversions via 
the Mitsunobu type reaction, such as using DEAD, Ph3P and 
an acid such as benZoic or p-nitrobenZoic acid, can be used. 
Frequently, the inversion via Mitsunobu needs protection of 
the other hydroxyl groups. Further details on the inversion 
via the Mitsunobu reaction can be found in Mitsunobu, 0., 
Synthesis, 1, 1981; or Hughes, D. L., Org. Reactions, 1992, 
42, 335. 
[0063] If the carbonyl group has already been functional 
iZed, then stronger oxidation conditions are needed, such as 
the use of RuCl3 or similar systems: 
[0064] Complete orthogonal and complete regioselective 
protection can be achieved from here by introduction of a 
further protecting group: 
H3O, Nu Pr3Q Nu 
HO,“ ‘ oPr1 1440,,” ' oPr1 
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[0065] The presence of vicinal hydroxyl groups allows the 
simultaneous protection of tWo of them through the use of 
diol protecting groups if desired. Among the diol protecting 
groups that can be used We have 0,0-acetals such as 
isopropylidene acetals (acetonides); cyclohexylidene and 
cyclopentylidene acetals; arylmethylene acetals; methylene 
acetals; diphenylmethylene acetals; 1,2-diacetals such as 
dispiroketal (dispoke) derivatives, cyclohexane-1,2-diac 
etals, butane-2,3-diacetals; silylene derivatives; 1,1,3,3-tet 
raisopropyldisiloxanylidene derivatives or N,O-acetals. 
Additional examples of diol protecting groups can be found 
in reference books such as Greene and Wuts’ “Protective 
Groups in Organic Synthesis”, John Wiley & Sons, Inc., 
NeW York, 1999. 
[0066] As can be understood from the above and Will be 
apparent to the person skilled in the art, due to the particular 
conformation and reactivity characteristics of the described 
compounds, a great number of possibilities can be achieved. 
It is important to point out that the obtained compounds of 
formula I Will present a carefully crafted functionality at the 
different positions 1-5 and the desired stereochemistry. The 
introduction of different protecting groups opens the route to 
very selective further reactions by chosing the appropriate 
protection-deprotection strategies. 
[0067] The process to obtain any of these compounds can 
be readily designed by starting from a compound of formula 
0 
HO H 
N 
O 
N W O 
\‘ 
O x 
<. ______ _. 
I" 
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IV above and then applying a basic set of reactions selected 
from: 
[0068] a) Hydroxilation or dihydroxylation: as above 
explained, using mild (such as OsO4/N oxide amine) or 
strong systems (such as RuCl3) depending on the 
position to be hydroxylated. Alternative systems are 
also envisaged. 
[0069] b) Nucleophilic attack at the carbonyl group: for 
example With a carbanion on a sp, sp2 or sp3 C, the 
carbanion can be prepared or generated in situ; or With 
an hydride. 
[0070] c) Hydroxyl inversion: as previously explained, 
for example through epimeriZation or inversion, for 
example in Mitsunobu conditions. 
[0071] d) Hydroxyl or carbonyl protection: as explained 
above, using the same or different protecting groups in 
conditions as explained above. 
[0072] Although each of these procedures is Well knoWn 
and the appropriate reagents can be selected by the person 
skilled in the art of organic synthesis, for example from 
those given in the references above, their application to the 
our structures gives unexpected results in terms of reactivity 
and selectivity. 
[0073] The folloWing scheme I illustrates some of the 
possibilities, When Z is —CH2— and Y is O: 
o 0 
OH OPr1 
OH OH 
N W N W \O/ \O/ 
o o 
[I 
O I’ ,1 
- - - - - - - - -> 
Pr40\\\\“ N\ /W 
O '\ 
O \\ \ 
\ 
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Scheme I 
[0074] Mixtures of different diasteroisomers can be sepa 
rated by conventional techniques. All the compounds Will be 
obtained as racemic mixtures. However, if enantiopurity is 
desired, this can be achieved by introducing a chiral center 
in the W group as explained above, or using chiral reagents 
or catalysts. Therefore the compounds of the present inven 
tion represented by the above described formula (I) may 
include pure enantiomers depending on the presence of 
stereogenic centers or diastereoisomers. The single isomers, 
enantiomers or diastereoisomers and mixtures thereof fall 
Within the scope of the present invention. 
[0075] Unless otherWise stated, the compounds of the 
invention are also meant to include compounds Which differ 
only in the presence of one or more isotopically enriched 
atoms. For example, compounds having the present struc 
tures except for the replacement of a hydrogen by a deute 
rium or tritium, or the replacement of a carbon by a 13C- or 
14C-enriched carbon or 15N-enriched nitrogen are Within the 
scope of this invention. 
[0076] Salts of compounds of the invention are synthe 
siZed from the parent compound Which contains a basic or 
acidic moiety by conventional chemical methods. Generally, 
such salts are, for example, prepared by reacting the free 
acid or base forms of these compounds With a stoichiometric 
amount of the appropriate base or acid in Water or in an 
organic solvent or in a mixture of the tWo. Generally, 
nonaqueous media like ether, ethyl acetate, ethanol, isopro 
panol or acetonitrile are preferred. Examples of the acid 
addition salts include mineral acid addition salts such as, for 
example, hydrochloride, hydrobromide, hydroiodide, sul 
phate, nitrate, phosphate, and organic acid addition salts 
such as, for example, acetate, maleate, fumarate, citrate, 
oxalate, succinate, tartrate, malate, mandelate, methane 
sulphonate and p-toluenesulphonate. 
[0077] The compounds of the invention may be in crys 
talline form either as free compounds or as solvates (e.g. 
hydrates) and it is intended that both forms are Within the 
scope of the present invention. Methods of solvation are 
generally knoWn Within the art. 
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[0078] The invention Will be further illustrated by means 
of examples. 
EXAMPLES 
General Methods and Materials 
[0079] All reactions described beloW Were carried out 
under argon atmosphere unless otherWise noted. The sol 
vents used Were distilled and dried under argon atmosphere 
before use. All starting materials Were purchased commer 
cially (Aldrich, Fluka and Merck) and used Without further 
puri?cation. Flash Chromatography Was executed on col 
umns loaded With 230-400 mesh silica gel Merck. TLC Was 
carried out on silica gel Merck (Kieselgel 6013-254). 
[0080] Melting points (mp) Were determined on a Reichert 
Microscopic Hot-Stage and are uncorrected. 1H and 13C 
NMR spectra Were measured on a Varian Gemini-200 and a 
Varian Inova-300 spectrometer With (CH3)4Si as an internal 
reference and CDCl3 as solvent unless otherWise noted. Both 
1H and 13C NMR spectral data are reported in parts per 
million (6) relative to residual sign of the solvent (CDCl3, 
7.26 ppm and 77.0 ppm for 1H and 13C NMR, respectively). 
1H and 13C NMR designations are: s (singlete); s br. (broad 
singlete); d (doublete); t (triplete); q (quartete); m (multip 
lete). Infrared (IR) spectra Were record on a Perkin-Elmer 
FT-IR spectrometer. UV spectra Were record on a Perkin 
Elmer 402 spectrometer. LoW-resolution mass (LRMS) 
spectra Were obtained on a HeWlett Packard 5973 MSD 
spectrometer With a direct inlet system (EI) at 70 eV. 
Microanalytical data Were obtained on a Perkin 
Elmer 240C and Heraus CHN—O instruments at the Instru 
mental Analysis Department of Instituto de Quimica 
Organica General (C.S.I.C.). 
[0081] The compounds beloW are nominated as deriva 
tives of 1-aZaspiro[3.5]nonan-2-one and numerated folloW 
ing the numeration described beloW. 
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Example 1 
Preparation of rac-(4R,5S,6S)- 1-benZyloxy-5 ,6 
dihidroxy- 1 -aZaspiro[3,5 ]nona-8-ene -2,7-dione (2) 
[0082] 
OSO4, NMO 
—> 
acetone-H2O [5 :1], r.t. 
[0083] To a solution of meso-1-benZyloxy-1-aZaspiro[3.5] 
nona-5,8-diene-2,7-dione (1) (804 mg, 3.150 mmol) in 
acetone (12 ml) Was added sequentially at room temperature 
H2O (2.4 ml), N-methylmorpholine N-oxide (812 mg, 6.930 
mmol) and osmium tetroxide (2.37 ml, 2.5 Wt. % solution in 
2-methyl-2-propanol, 0.189 mmol). The resultating mixture 
Was stirred at room temperature until the reaccion Was 
complete (1 h, TLC monitoring, AcOEt), and then quenched 
With 10% aqueous Na2S2O3 solution (3 ml). After 20 min, 
the mixture Was extrated With AcOEt (5><6 ml). The com 
bined organic extracts Were dried over Na2SO4, ?ltered and 
concentrated under reduced pressure. The residue Was puri 
?ed by silica gel column chromatography (hexane-AcOEt, 
3:2) to give rac-(4R,5S,6S)-1-benZyloxy-5,6-dihidroxy-1 
aZaspiro[3.5]nona-8-ene-2,7-dione (2) as a White solid (419 
mg, 46%). 
[0084] Rf=0.47 (TLC, AcOEt); yield, 46%; White solid; 
1H-NMR (200 MHZ, CD3OD): 6 7.56 (5H, s, Ph), 6.69 (1H, 
part A syst. AB, J9)8=10.1 HZ, H-9), 6.65 (1H, part B syst. 
AB, J8)9=10.1 HZ, H-8), 5.19 (1H, part A syst. AB, J=11.2 
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HZ, OCHZPh), 5.14 (1H, part B syst. AB, J=11.2 HZ, 
OCEZPh), 4.56 (1H, d, J=2.9 HZ, H-6), 4.31 (1H, m, H-5), 
3.32 (1H, part A syst. AB, J=14.4 HZ, H-3), 2.93 (1H, part 
B syst. AB, J=14.4, H-3); 13c-NMR (75 MHZ, CD3OD): 6 
199.0, 167.0, 146.8, 136.7, 131.2, 131.1, 130.1, 80.9, 76.1, 
74.2, 67.3, 434; IR (KBr): v 3429, 1772, 1692, 1631, 1450, 
1382, 1053, 698 cm_1; LRMS (API-ES”): III/Z 312 
(M+Na)+, 290 (M+H)+. 
Example 2 
Preparation of rac-(4R,5S,6S)-1-benZyloxy-6-tert 
butyldimethylsilyloxy-5-hydroxy-1-aZaspiro[3.5] 
nona-8-ene-2,7-dione (3) 
[0085] 
TBDMSCl, imidazole 
DMF, 00 C. to r.t. 
[0086] To a solution of rac-(4R,5S,6S)-1-benZyloxy-5,6 
dihydroxy-1-aZaspiro[3.5]nona-8-ene-2,7-dione (2) (123 
mg, 0.425 mmol) and imidaZole (35 mg, 0.510 mmol) in 
DMF (0.6 ml) Was added at 0° C. a solution of tert 
butyldimethylsilyl chloride (77 mg, 0.510 mmol) in DMF 
(1.2 ml). After 12 h at room temperature, the reaction Was 
quenched With H20 (3 ml) and the mixture extracted With 
AcOEt (3><5 ml). The combined extracts Were Washed With 
saturated aqueous CuSO4 solution (2><10 ml) and brine 
(2><10 ml), dried over Na2SO4, ?ltered and concentrated 
under reduced pressure. The residue Was puri?ed by silica 
gel column chromatography (hexane-AcOEt, 5:2) to give 
rac-(4R,5S,6S)-1-benZyloxy-6-tert-butyldimethylsilyloxy 
5-hydroxy-1-aZaspiro[3.5]nona-8-ene-2,7-dione (3) as a 
White solid (133 mg, 78%). 
[0087] Rf=0.56 (TLC, hexane-AcOEt, 1:1); yield, 78%; 
White SOlld; 1H-NMR (200 MHZ, CDC13): 6 7407.29 (5H, 
m, Ph), 6.24 (1H, part A syst. AB, J9)8=10.1 HZ, H-9), 5.78 
(1H, part B syst. AB, J8)9=10.1 HZ, H-8), 5.00 (1H, part A 
syst. AB, J=11.4 HZ, OCHJPh), 4.87 (1H, part B syst. AB, 
J=11.4 HZ, OCEZPh), 4.36 (1H, d, J=2.7 HZ, H-6), 4.01 (1H, 
m, H-5), 3.25 (1H, part A syst. AB, J=14.6 HZ, CH2), 2.63 
US 2005/0261492 A1 
(1H, part B syst. AB, J=14.6 HZ, CH2), 2.56 (1H, d, J=3.8 
HZ, 0H), 0.85 (9H, s, C(CH3)3), 0.09 (3H, s, SiCH3), 0.08 
(3H, s, SiCH3); 13c-NMR (75 MHZ, CDC13): 6 195.4, 165.5, 
145.2, 134.9, 129.6, 129.5, 129.3, 128.8, 79.3, 75.5, 71.7, 
64.7, 41.9, 25.6, 18.1, 4.9, -5.3, IR (KBr): v 3453, 2949, 
2929, 2855, 1767, 1682, 1256, 1119, 1088, 980, 843, 782 
cm_1; LRMS (API-ES”): m/Z 829 (2M+Na)+, 426 (M+Na)+, 
404 (M+H)+. 
Example 3 
Preparation of rac-(4R,5S,6S,8S,9S)-1-benZyloxy-6 
tert-butyldimethylsilyloxy-5,8,9-trihydroxy-1-aZa 
spiro[3.5]nona-2,7-dione (4) 
[0088] 
OsO4, NMO 
—
acetone-H2O [5:1], r.t. 
[0089] To a stirred solution of rac-(4R,5S,6S)-1-benZy 
loxy-6-tert-butyldimethylsilyloxy-5-hydroxy-1-aZaspiro 
[3.5]nona-8-ene-2,7-dione (3) (50 mg, 0.124 mmol) in 
acetone (0.45 ml) Was added sequentially at room tempera 
ture H2O (0.09 ml), N-methylmorpholine N-oxide (58 mg, 
0.496 mmol) and osmium tetroxide (93 pl, 2.5 Wt. % 
solution in 2-methyl-2-propanol, 7.4-10'3 mmol). The 
resulting mixture Was stirred at room temperature until the 
reaction Was complete (18 h, TLC monitoring, hexane 
AcOEt, 1:1), and then quenched With 10% aqueous Na2S2O3 
solution (20 drops). After 20 min, the mixture Was ?ltered 
through silica gel With MeOH and concentrated under 
reduced pressure. The residue Was puri?ed by silica gel 
column chromatography (hexane-AcOEt, 2:1) to give rac 
(4R,5S,6S,8S,9S)-1-benZyloxy-6-tert-butyldimethylsily 
loxy-5,8,9-trihydroxy-1-aZaspiro[3.5]nona-2,7-dione (4) as 
a White solid (26 mg, 48%). 
[0090] Rf=0.46 (TLC, hexane-AcOEt, 1:1); yield, 48%; 
White solid; 1H-NMR (200 MHZ, CDC13): 6 749-730 (5H, 
m, Ph), 5.11 (1H, partAsyst. AB, J=10.6 HZ, OCHJPh), 5.05 
(1H, part B syst. AB, J=10.6 HZ, OCEZPh), 4.68 (1H, dd, 
J=4.3, 3.7 HZ, H-8), 4.44-4.32 (2H, m, H-5 and H-6), 4.22 
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(1H, dd, J=1.8, 1.5 HZ, H-9), 3.48 (1H, d, J=4.3 HZ, 
HO—C(8)), 3.36 (1H, part A syst. AB, J=14.3 HZ, CH2), 
2.73 (1H, d, J=1.8 HZ, HO—C(9)), 2.45 (1H, part B syst. 
AB, J=14.3 HZ, CH2), 2.28 (1H, s br, Ho_c(5)), 0.85 (9H, 
s, C(CH3)3), 0.13 (3H, s, SiCH3), 0.04 (3H, s, SiCH3); 
13c-NMR (75 MHZ, CDC13): 6 204.8, 166.1, 135.1, 129.4, 
129.0, 128.5, 78.9, 76.4, 75.5, 72.2, 67.4, 65.7, 37.5, 25.6, 
18.0, -5.0, -5.3, IR (KBr): v 3435, 2949, 2927, 2855, 1761, 
1740, 1631, 1261, 1110, 1078, 837 cm_1; LRMS (API-ES”): 
III/Z 897 (2M+Na)+, 460 (M+Na)+, 438 (M+H)+. 
Example 4 
Preparation of rac-(4R,5S,6S,8S,9S)-1 -benZyloxy-6 
tert-butyldimethylsilyloxy-5 -hydroxy-8,9-dimethyl 
methylendioxy- 1 -aZaspiro[3 .5 ]nona-2,7-dione (5) 
[0091] 
2,2-dimethoxypropane 
—>
p-TsOH, acetone, r.t. 
[0092] To a stirred solution of rac-(4R,5S,6S,8S,9S)-1 
benZyloxy-6-tert-butyldimethylsilyloxy-5,8,9-trihydroxy-1 
aZaspiro[3.5]nona-2,7-dione (4) (50 mg, 0.115 mmol) and 
2,2-dimethoxypropane (71 pl, 0.575 mmol) in dry acetone 
(0.5 ml) Was added at room temperature catalytic amount of 
p-TsOH (1% mmol). The resulting mixture Was stirred at 
room temperature for 18 h, then quenched With saturated 
aqueous NaZCO3 solution (1 ml) and extracted With AcOEt 
(3><2 ml). The combined organic extracts Were Washed With 
brine (3 ml), dried over Na2SO4, ?ltered and concentrated 
under reduced pressure. The residue Was puri?ed by silica 
gel column chromatography (hexane-AcOEt, 3:1) to give 
rac-4R,5S,6S,8S,9S)-1-benZyloxy-6-tert-butyldimethylsily 
loxy-5-hydroxy-8,9-dimethylmethylendioxy-1-aZaspiro 
[3.5]nona-2,7-dione (5) as a White solid (27 mg, 49%) and 
unreacted starting material (5) (13 mg, 24%). 
[0093] Rf=0.77 (TLC, hexane-AcOEt, 1:1); yield, 49%; 
White solid; 1H-NMR (200 MHZ, CDC13): 6 7.40734 (5H, 
m, Ph), 5.05 (1H, partAsyst.AB, J=10.2 HZ, OCHZPh), 5.02 
(1H, part B syst. AB, J=10.2 HZ, OCEZPh), 4.84 (1H, d, 
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J=5.4 HZ, H-8), 4.45 (1H, d, J=5.4 HZ, H-9), 4.39 (1H, d, 
J=2.7 HZ, H-6), 4.35 (1H, dd, J=5.9, 2.7 HZ, H-5), 3.45 (1H, 
part A syst. AB, J=14.2 HZ, CH2), 2.56 (1H, d, J=5.9 Hz, 
0H), 2.48 (1H, part B syst. AB, J=14.2 HZ, CH2), 0.86 (9H, 
s, C(CH3)3), 0.11 (3H, s, SiCH3), 0.06 (3H, s, SiCH3); 
13c-NMR (75 MHZ, CDC13): 6 203.6, 165.8, 135.0, 129.3, 
128.9, 128.5, 111.3, 79.8, 79.0, 78.9, 77.7, 66.1, 65.4, 39.4, 
26.9, 25.9, 25.5, 18.0, -5.1, -5.3, IR (KBr): v 3434, 2930, 
2855, 1764, 1739, 1628, 1453, 1384, 1255, 1225, 1111, 
1086, 898, 832, 784 cm_1; LRMS (API-ES”): III/Z 977 
(2M+Na)+, 500 (M+Na)+, 478 (M+H)+. 
Example 5 
Preparation of rac-(4R,5S,65)-1-benZyloxy-6-tert 
butyldimethylsilyloxy-5-trimethylsilyloxy-1-aZa 
spiro[3.5]nona-8-ene-2,7-dione (6) 
[0094] 
TMS-imidazole 
[0095] A solution of rac-(4R,5S,6S)-1-benZyloxy-6-tert 
butyldimethylsilyloxy-5-hydroxy-1-aZaspiro[3.5]nona-8 
ene-2,7-dione (3) (130 mg, 0.322 mmol) in 1-trimethylsi 
lylimidaZole (0.5 ml, 3.220 mmol) Was stirred at room 
temperature for 16 h. The reaction Was quenched With 
NaZPO4 0.1 M buffer (2 ml) and the mixture extracted With 
AcOEt (3><4 ml). The combined extracts Were Washed With 
saturated aqueous CuSO4 solution (1><8 ml) and brine (2><8 
ml), dried over Na2SO4, ?ltered and concentrated under 
reduced pressure. The residue Was puri?ed by silica gel 
column chromatography (hexane-AcOEt, 5:1) to give rac 
(4R,5S,6S)-1-benZyloxy-6-tert-butyldimethylsilyloxy-5-tri 
methylsilyloxy-1-aZaspiro[3.5]nona-8-ene-2,7-dione (6) as 
a White solid (100 mg, 65%). 
[0096] Rf=0.50 (TLC, hexane-AcOEt, 3:1); yield, 65%; 
White solid; 1H-NMR (200 MHZ, CDC13): 6 742-728 (5H, 
m, Ph), 6.09 (1H, partAsyst. AB, J9)8=10.3 HZ, H-9), 5.68 
(1H, part B syst. AB, J8)9=10.3 HZ, H-8), 4.98 (1H, part A 
syst. AB, J=11.6 HZ, OCHZPh), 4.84 (1H, part B syst. AB, 
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J=11.6 HZ, ocH2Ph), 4.13 (2H, d, J=2.4 HZ, H-5 and H-6), 
3.40 (1H, m, CH2), 2.47 (1H, d, J=14.2 HZ, CH2), 0.79 (9H, 
s, C(CH3)3), 0.16 (9H, s, Si(CH3)3), 0.08 (3H, s, SiCH3), 
0.00 (3H, s, SiCH3); LRMS (API-ES”): III/Z 973 (2M+Na)+, 
498 (M+Na)+, 476 (M+H)+, LRMS (EI): III/Z 475 (M*, 3), 
460 (2), 418 (21), 384(5), 368 (4), 354(6), 340(4), 324 (3), 
309 (13), 269 (43), 179 (24), 147 (34), 91 (100), 73 (57). 
Example 6 
Preparation of rac-(4R,5S,6S,7S)- 1 -benZyloxy-6 
tert-butyldimethylsilyloxy-7-cyano -5 ,7-bis(trimeth 
ylsilyloxy)- 1 -aZaspiro[3 .5 ]nona-8-ene -2-one 
[0097] 
TMSCN 
—> 
DABCO (10 mol%), r.t. 
[0098] To a mixture of rac-(4R,5S,6S)-1-benZyloxy-6 
tert-butyldimethylsilyloxy-1-aZaspiro[3.5]nona-8-ene-2,7 
dione (3) (200 mg, 0.496 mmol) and trimethylsilyl cyanide 
(607 pl, 4.460 mmol) at room temperature (cooled With 
Water bath) Was sloWly added DABCO (6 mg, 0.050 mmol). 
The mixture Was stirred at room temperature for 14 h and 
then concentrated under reduced pressure. The residue Was 
puri?ed by silica gel column chromatography (hexane 
AcOEt, 5:1) to give rac-(4R,5S,6S,7S)-1-benZyloxy-6-tert 
butyldimethylsilyloxy-7-cyano-5,7-bis(trimethylsilyloxy) 
1-aZaspiro[3.5]nona-8-ene-2-one (7) as a orange solid (254 
mg, 89%). 
[0099] Rf=0.61 (TLC, hexane-AcOEt, 3:1); yield, 89%; 
orange solid; 1H-NMR (300 MHZ, CDCl3): 0 7.37 (5H, s, 
Ph), 5.72 (1H, d, J=10.0 HZ, H-9), 5.21 (1H, dd, J=10.0, 1.9 
HZ, H-8), 4.96 (1H, part Asyst. AB, J=11.6 HZ, OCHJPh), 
4.82 (1H, part B syst. AB, J=11.6 HZ, OC?zPh), 4.49 (1H, 
d, J=1.5 HZ, H-6), 4.10 (1H, t, J=1.9, 1.5 HZ, H-5), 3.32 (1H, 
partAsyst. AB, J=13.8 HZ, H-3), 2.26 (1H, partAsyst. AB, 
J=13.8 HZ, H-3), 0.80 (9H, s, C(CH3)3), 0.28 (9H, s, 
Si(CH3)3), 0.20 (9H, s, Si(CH3)3), 0.09 (3H, s, SiCH3), 0.04 
(3H, s, SiCH3); 13c-NMR (75 MHZ, CDC13): 6 165.7, 135.6, 
132.6, 129.3, 128.8, 128.7, 126.9, 119.7, 78.8, 78.6, 69.8, 
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67.0, 65.6, 40.6, 25.8, 18.2, 1.4, 0.2, -4.1, 4.6, -70, IR 
(NaCl, cc14); v 2957, 2891, 2855, 1785, 1255, 1101, 878, 
843,753 cm_1; LRMS (API-ES”): III/Z 1171 (2M+Na)+, 598 
(M+Na)+, 575 (M+H)+. 
Example 7 
Preparation of rac-(4R,5S,6S,7S)-1-benZyloxy-7 
cyano-5,6,7-tris(trimethylsilyloxy)-1-aZaspiro[3.5] 
nona-8-ene-2-one (8) 
[0100] 
TMSCN 
—> 
DABCO (10 mol%), r.t. 
[0101] To a mixture of rac-(4R,5S,6S)-1-benZyloxy-5,6 
dihydroxy-1-aZaspiro[3.5]nona-8-ene-2,7-dione (2) (44 mg, 
0.152 mmol) and trimethylsilyl cyanide (186 pl, 1.368 
mmol) at room temperature (cooled With Water bath) Was 
slowly added DABCO (2 mg, 0.015 mmol). The mixture 
Was stirred at room temperature for 14 h and then concen 
trated under reduced pressure. The residue Was puri?ed by 
silica gel column chromatography (hexane-AcOEt, 5:1) to 
give rac-(4R,5S,6S,7S)-1-benZyloxy-7-cyano-5,6,7-tris(tri 
methylsilyloxy)-1-aZaspiro[3.5]nona-8-ene-2-one (8) as a 
yelloW solid (51 mg, 62%). 
[0102] Rf=0.50 (TLC, hexane-AcOEt, 3:1); yield, 62%; 
yelloW solid; 1H-NMR (200 MHZ, CDCl3): 6 7.37 (5H, s br, 
Ph), 5.33-5.20 (2H, m, H-8 and H-9), 4.96 (1H, partA syst. 
AB, J=11.6 HZ, OCHZPh), 4.81 (1H, part B syst. AB, J=11.6 
HZ, OCHZPh), 4.41 (1H, d, J=1.5 HZ, H-5 Or H-6), 4.08 (1H, 
t, J=1.5 HZ, H-6 or H-5), 3.27 (1H, part A syst. AB, J=14.1 
HZ, CH2), 2.27 (1H, part B syst. AB, J=14.1 HZ, CH2), 0.27 
(9H, s, Si(CH3)3), 0.20 (9H, s, Si(CH3)3), 0.08 (9H, s, 
Si(CH3)3); 13c-NMR (75 MHZ, CDC13): 6 165.9, 135.6, 
132.8, 129.2, 128.8, 128.7, 126.7, 119.6, 78.8, 78.4, 69.4, 
66.8, 65.5, 40.3, 1.3, 0.4, 02, IR (NaCl, CC14): 3391, 2958, 
2898, 2222, 1785, 1455, 1400, 1253, 1168, 1104, 1030, 880, 
843, 752 cm_1; LRMS (API-ES”): III/Z 1087 (2M+Na)+, 555 
(M+Na)+, 533 (M+H)+. 
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Example 8 
Preparation of rac-(4R,5S,6S,7S)-1-benZyloxy-7 
cyano-6-tert-butyldimethylsilyloxy-5,7-bis(methoxy 
carbonyloxy)-1-aZaspiro[3.5]nona-8-ene-2-one (9) 
[0103] 
NC—CO2CH3 
—> 
DABCO (10 mol%), r.t. 
[0104] To a mixture of rac-(4R,5S,6S)-1-benZyloxy-6 
tert-butyldimethylsilyloxy-5-hydroxy-1-aZaspiro[3.5]nona 
8-ene-2,7-dione (3) (95 mg, 0.235 mmol) and methylcyano 
formate (169 pl, 2.115 mmol) Was added at room 
temperature DABCO (3 mg, 0.023 mmol). The mixture Was 
stirred at room temperature for 14 h and then concentrated 
under reduced pressure. The residue Was triturated With 
EtZO, ?ltered and the solvent Was evaporated under reduced 
pressure to give rac-(4R,5S,6S,7S)-1-benZyloxy-7-cyano-6 
tert-butyldimethylsilyloxy-5,7-bis(methoxycarbonyloxy)-1 
aZaspiro[3.5]nona-8-ene-2-one (9) as a broWn oil (110 mg, 
86%), Was used in the next reaction Without further puri? 
cation. 
[0105] Rf=0.65 (TLC, hexane-AcOEt, 1:1); yield, 86%; 
broWn oil; 1H-NMR (200 MHZ, CDCl3): 6 7.39 (5H, s br, 
Ph), 5.73 (1H, dd, J=10.3, 2.0 HZ, H-8 Or H-9), 5.46 (1H, d, 
J=10.3 HZ, H-9 Or H-8), 5.40 (1H, d, J=1.8 HZ, H-5 Or H-6), 
4.95 (1H, part A syst. AB, J=11.5 HZ, OCHZPh), 4.87 (1H, 
part B syst. AB, J=11.5 HZ, OCHZPh), 4.77 (1H, dd, J=2.0, 
1.8 HZ, H-6 Or H-5), 3.85 (3H, s, OCH3), 3.84 (3H, s, 
OCH3), 3.29 (1H, part A syst. AB, J=14.4 HZ, CH2), 2.44 
(1H, part B syst. AB, J=14.4 HZ, CH2), 0.79 (9H, s, 
C(CH3)3), 0.07 (3H, s, SiCH3), 0.04 (3H, s, SiCH3); 13c 
NMR (75 MHZ, CDC13): 6 165.5, 154.2, 152.9, 135.2, 
133.9, 129.4, 129.3, 129.0, 128.9, 123.2, 115.1, 79.1, 72.5, 
72.3, 70.9, 63.1, 55.7, 55.5, 41.7, 25.5, 25.1, 17.9, -4.5, 
-5.5, IR (NaCl, CC14): 3355, 2958, 2927, 2855, 2233, 1786, 
1763, 1442, 1274, 1255, 1155, 1050, 834, 783 cm_1; LRMS 
(API-ES”): III/Z 1115 (2M+Na)+, 569 (M+Na)+, (M+H)+; 
LRMS (EI): III/Z 546 (M*, 2), 489 (5), 455 (1), 413 (3), 337 
(18), 323 (4), 295 (17), 216 (10), 190 (17), 133 (16), 91 
(100). 
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Example 9 
Preparation of rac-(4R,5S,6S,7S,8S,9S)-1-benZy 
loxy-6-ter-butyldimethylsilyloxy-7-cyano-8,9-dihy 
droxy-5,7-bis(trimethylsilyloxy)-1-aZaspiro[3.5] 
nona-2-one (10). 
[0106] 
10 
[0107] To a solution of rac-(4R,5S,6S,7S)-1-benZyloxy-6 
tert-butyldimethylsilyloxy-7-cyano-5,7-bis(trimethylsily 
loxy)-1-aZaspiro[3.5]nona-8-ene-2-one (7) (100 mg, 0.174 
mmol) in AcOEt (1 ml) and CH3CN (1 ml) Was added at 0° 
C. With vigorous stirring a solution of ruthenium (III) 
chloride hydrate (9 mg, 0.043 mmol) and sodium periodate 
(71 mg, 0.331 mmol) in H2O (0.35 ml). After 5 min the 
reaction the mixture Was quenched With saturated aqueous 
sodium hydrogensul?te solution (2 ml) and extracted With 
AcOEt (3><2 ml). The combinted organic extracts Were dried 
over MgSO4, ?ltered and concentrated under reduced pres 
sure. The residue Was puri?ed by silica gel column chro 
matography (hexane-AcOEt, 5 :1) to give rac-(4R,5S,6S,7S, 
8S,9S)-1-benZyloxy-6-tert-butyldimethylsilyloxy-7-cyano 
8,9-dihydroxy-5,7-bis(trimethylsilyloxy)-1-aZaspiro[3.5] 
nona-2-one (10) as a White solid (73 mg, 69%). 
[0108] Rf=0.33 (TLC, hexane-AcOEt, 3:1); yield, 69%; 
White solid; 1H-NMR (200 MHZ, CDC13): 6 747-733 (5H, 
m, Ph), 5.21 (1H, partAsyst. AB, J=10.1 HZ, OCHZPh), 5.02 
(1H, part B syst. AB, J=10.1 HZ, OCHZPh), 4.74 (1H, d, 
J=2.1 HZ, H-8 Or H-7), 4.10 (1H, d, J=2.1 HZ, H-7 Or H-8), 
3.92 (1H, H1, H6 Or H-5), 3.83 (1H, H1, H5 Or H-6), 3.27 
(1H, partAsyst. AB, J=14.0 HZ, H-3), 3.27 (1H, s, OH), 2.15 
(1H, part B syst. AB, J=14.0 HZ, H-3), 2.01 (1H, s, OH), 
0.86 (9H, s, C(CH3)3), 0.30 (9H, s, Si(CH3)3), 0.14 (3H, s, 
SiCH3), 0.13 (9H, s, Si(CH3)3), 0.11 (3H, s, SiCH3); 13c 
NMR (50 MHZ, CDC13): 6 166.0, 134.9, 128.9, 128.5, 
119.3, 97.1, 78.9, 78.7, 74.8, 73.9, 70.9, 68.8, 65.2, 38.6, 
26.1, 18.3, 1.8, 0.4, -3.8, -50; IR (KBr): v 3434, 3028, 
2957, 2927, 2898, 2855, 2152, 1762, 1630, 1253, 1169, 
1107, 846, 740 CHI-1; LRMS (API-ES”): III/Z 1240 (2M+ 
Na)", 631 (M+Na)+, 609 (M+H)+. 
12 
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Example 10 
Preparation of rac-(4R,5S,6S,7S,8S,9S)-1-benZy 
loxy-6,8-bis(tert-butyldimethylsilyloxy)-7-cyano-9 
hydroxy-5,7-bis(trimethylsilyloxy)-1-aZaspiro[3.5] 
nona-2,7-dione (11) 
[0109] 
H0,” 
\\\ TBDMSCl, imidazole 
Ho‘ 
DMF, 0° C. to r.t. 
PiJ 
10 
[0110] To a solution of rac-(4R,5S,6S,7S,8S,9S)-1-benZy 
loxy-6-tert-butyldimethylsilyloxy-7-cyano-8,9-dihydroxy 
5,7-bis(trimethylsilyloxy)-1-aZaspiro[3.5]nona-2,7-dione 
(10) (63 mg, 0.103 mmol) and imidaZole (8 mg, 0.124 
mmol) in DMF (0.25 ml) Was added at 0° C. a solution of 
tert-butyldimethylsilyl chloride (19 mg, 0.124 mmol) in 
DMF (0.5 ml). After 16 h at room temperature, the reaction 
Was quenched With H20 (2 ml) and the mixture extracted 
With AcOEt (3><4 ml). The combined extracts Were Washed 
With saturated aqueous CuSO4 solution (2x8 ml) and brine 
(2x8 ml), dried over Na2SO4, ?ltered and concentrated 
under reduced pressure. The residue Was puri?ed by silica 
gel column chromatography (hexane-AcOEt, 5:1) to give 
rac-(4R,5S,6S,7S,8S,9S)-1-benZyloxy-6,8-bis(tert-bu 
tyldimethylsilyloxy)-7-cyano-9-hydroxy-5,7-bis(trimethyl 
silyloxy)-1-aZaspiro[3.5]nona-2,7-dione (11) as a White 
solid (37 mg, 46%). 
[0111] Rf=0.60 (TLC, hexane-AcOEt, 3:1); yield, 46%; 
White solid; 1H-NMR (200 MHZ, CO(CD3)2): 6 7.54-7.42 
(2H, m, Ph), 7.41-7.29 (3H, m, Ph), 5.26 (1H, part A syst. 
AB, J=10.2 HZ, OCHZPh), 5.06 (1H, part B syst. AB, J=10.2 
HZ, OCHZPh), 4.82 (1H, d, J=2.4 HZ, H-5), 4.70 (1H, d, 
J=2.4 HZ, 0H), 4.27 (1H, d, J=2.4 HZ, H-6), 4.16 (1H, In, 
H-9), 3.99 (1H, s br, H-8), 3.23 (1H, partAsyst. AB, J=13.7 
HZ, CH2), 2.89 (1H, part B syst. AB, J=13.7 HZ, CH2), 0.91 
(18H, s, C(CH3)3), 0.19 (6H, s, SiCH3), 0.18 (6H, s, SiCH3), 
0.11 (18H, s, Si(CH3)3). 
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Example 11 
General Procedure for the Preparation of the 
Silylcyanohydrin 12a and 12b from the Spiro 
[3-Lactams 1a and 1b, Respectively 
[0112] 
TMSCN 
—> 
DABCO (10 mol%), r.t. 
1a R = CHZPh 
1b R = CH3 
12a R = CHZPh 
12b R = CH3 
[0113] To a mixture of spiro [3-lactams 1a-b (0.588 mmol) 
and trimethylsilyl cyanide (1.763 mmol) at room tempera 
ture (cooled With Water bath) Was slowly added DABCO (10 
mol %). The mixture Was stirred at room temperature until 
the disappearance of starting material by TLC (hexane 
AcOEt, 1:1) Was observed (the time required Was 6 h for 1a 
and 24 h for 1b), and then concentrated under reduced 
pressure. The silylcyanohydrin 12a-b isolated by procedure 
could be used Without further puri?cation (the puri?cation 
by silica gel column chromatography to give mixtures of 
silylcyanohydrin 12a-b and starting material 1a-b). 
[0114] rac-(4R,7S) and (4R,7R)-1-benZyloxy-7-cyano-1 
aZaspiro[3.5]nona-5,8-diene-2-one (12a) Rf=0.64 (TLC, 
hexane-AcOEt, 1:1); yield, 88%; broWn solid; 1H-NMR 
(200 MHZ, CDCl3): 6 7.37 (5H, m Ph), 7.35 (5H, m, Ph), 
6.09 (2H, part AA‘ syst. AA‘BB‘, J5)6=10. HZ, CH=CHCO), 
6.06 (2H, part AA‘ syst. AA‘BB‘, J5)6=10.1 HZ, 
CH=CHCO), 5.87 (2H, part BB‘ syst. AA‘BB‘, J6>5=10.1 
HZ, CH=CHCO), 5.79 (2H, part BB‘ syst. AA‘BB‘, J6>5= 
10.1 HZ, CH=CHCO), 4.89 (2H, s, OCHZPh), 4.87 (2H, s, 
OCHZPh), 2.75 (2H, s, CH2), 2.73 (2H, s, CH2), 0.26 (9H, 
s, Si(CH3)3), 0.19 (9H, s, Si(CH3)3). 
[0115] rac-(4R,7S) and 4R,7R)-1-methoxy-7-cyano-1 
aZaspiro[3.5]nona-5,8-diene-2-one (12b) Rf=0.61 (TLC, 
hexane-AcOEt, 1:2); yield, 64%; broWn solid; 1H-NMR 
(200 MHZ, CDCl3): 6 6.26 (2H, part AA‘ syst. AA‘BB‘, 
J5)6=10.1 HZ, CH=CHCO), 6.21 (2H, part AA‘ syst. 
AA‘BB‘, J5)6=10.1 HZ, CH=CHCO), 6.09 (2H, part BB‘ 
syst. AA‘BB‘, J6>5=10.1 HZ, CH=CHCO), 6.08 (2H, part 
BB‘ syst. AA‘BB‘, J6>5=10.1 HZ, CH=CHCO), 3.76 (6H, s, 
OCH3), 2.81 (2H, s, CH2), 2.80 (2H, s, CH2), 0.24 (9H, s, 
Si(CH3)3), 0.23 (9H, s, Si(CH3)3). 
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Example 12 
Preparation of rac-4R,5S,6S)-1-benZyloxy-5,6-dim 
ethylmethylendioxy-1-aZaspiro[3.5]nona-8-ene-2,7 
dione (13) 
[0116] 
OH 
2,2-dimethoxypropane 
OH —>
p-TsOH, acetone, r.t. 
PhJ 
13 
[0117] To a stirred solution of rac-(4R,5S,6S)-1-benZy 
loxy-5,6-dihydroxy-1-aZaspiro[3.5]nona-8-ene-2,7-dione 
(2) (109 mg, 0.377 mmol) and 2,2-dimethoxypropane (0.24 
ml, 1.885 mmol) in dry acetone (0.75 ml) Was added at room 
temperature catalytic amount of p-TsOH (1% mmol). The 
resulting mixture Was stirred at room temperature for 18 h, 
then quenched With saturated aqueous NaZCO3 solution (1 
ml) and extracted With AcOEt (3><2 ml). The combined 
organic extracts Were Washed With brine (3 ml), dried over 
Na2SO4, ?ltered and concentrated under reduced pressure. 
The residue Was puri?ed by silica gel column chromatog 
raphy (hexane-AcOEt, 5:2) to give rac-(4R,5S,6S)-1-benZy 
loxy-5,6-dimethylmethylendioxy-1-aZaspiro[3.5]nona-8 
ene-2,7-dione (13) as a solid (52 mg, 42%). 
[0118] Rf=0.50 (TLC, hexane-AcOEt, 1:1); yield, 42%; 
solid; 1H-NMR (200 MHZ, CDCl3): 6 7.50-7.22 (5H, m, 
Ph), 6.28 (1H, partAsyst. AB, J9>8=9.9 HZ, H-9), 5.91 (1H, 
part B syst. AB, J8>9=9.9 HZ, H-8), 4.95 (1H, partAsyst. AB, 
J=11.4 HZ, OCHZPh), 4.85 (1H, part B syst. AB, J=11.4 HZ, 
OCHZPh), 4.27 (1H, part Asyst. AB, J=5.1 HZ, H-5 or H-6), 
4.11 (1H, part B syst. AB, J=5.1 HZ, H-6 or H-5), 6.37 (1H, 
partAsyst. AB, J=15.0 HZ, CH2), 2.79 (1H, part B syst. AB, 
J=15.0 HZ, CH2), 1.34 (3H, s, CH3), 1.27 (3H, s, CH3). 
1. A compound of formula I 
formula I 
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wherein 
R1, R2, R3, R4 are each independently selected from H, 
OH or OPr; 
R5 and R6 together are :0 or R5 is selected from H, OH, 
OPr and R6 is selected from hydrogen, cyano, substi 
tuted or unsubstituted alkyl, substituted or unsubsti 
tuted cycloalkyl, substituted or unsubstituted alkenyl, 
substituted or unsubstituted alkynyl, substituted or 
unsubstituted aryl, substituted or unsubstituted hetero 
cyclyl, With the proviso that at least one of R1, R2, R3, 
R4 or R5 is OH or OPr; 
Pr is an hydroXy protecting group Which can be the same 
or different on each of R1, R2, R3, R4 or R5; 
the dotted line represents a single or double bond With the 
proviso that When both R1 and R2, or R3 and R4, are H 
then there is a double bond betWeen the tWo C to Which 
the H are linked; 
Z is —(CRaRb)n— Wherein n is a number selected from 
1, 2, 3 and Ra and Rb are each independently selected 
from hydrogen, substituted or unsubstituted alkyl, sub 
stituted or unsubstituted cycloalkyl, substituted or 
unsubstituted alkenyl, substituted or unsubstituted aryl, 
substituted or unsubstituted heterocyclyl, substituted or 
unsubstituted alkoXy, substituted or unsubstituted ary 
loXy, substituted or unsubstituted amino or halogen; 
Y is selected from —O—, —S—, —N(RaRb)— or 
—C(O)—, Wherein Ra and Rb are as previously 
de?ned and do not form a cyclic ring; 
W is a group selected from substituted or unsubstituted 
arylalkyl, substituted or unsubstituted heterocyclyla 
lkyl, substituted or unsubstituted alkenyl; 
or a salt, complex or solvate thereof. 
2. A compound according to claim 1 characteriZed in that 
Z is —(CHRa)n—, Ra and n being as de?ned in claim 1. 
3. A compound according to claim 1 characteriZed in that 
n is 1. 
4. A compound according to claim 3 characteriZed in that 
Z is —CH2—. 
5. A compound according to claim 1 characteriZed in that 
Y is —O—. 
6. Acompound as de?ned in claim 1 characteriZed in that 
W is —CRaRb-Q, Wherein Ra and Rb are as previously 
de?ned and Q is substituted or unsubstituted aryl, substi 
tuted or usubstituted heterocyclyl, substituted or unsubsti 
tuted alkenyl. 
7. Acompound as de?ned in claim 6 characteriZed in that 
Ra and Rb are H. 
8. Acompound as de?ned in claim 6 characteriZed in that 
Q is aryl. 
9. Acompound as de?ned in claim 1 characteriZed in that 
the hydroXyl protecting goup Pr is independently selected 
from silyl ethers, alkyl ethers, allyl ethers; alkoXymethyl 
ethers, aryloXymethyl ethers, acetate ester, benZoate ester; 
pivalate ester, methoXyacetate ester, chloroacetate ester, 
levulinate ester, methyl carbonate, benZyl carbonate, p-ni 
trobenZyl carbonate, tert-butyl carbonate, 2,2,2-trichloroet 
hyl carbonate, 2--(trimethylsilyl)ethyl carbonate allyl car 
bonate, isopropylidene acetals; cyclohexylidene and 
cyclopentylidene acetals; arylmethylene acetals; methyl 
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ene acetals; diphenylmethylene acetals; 1,2-diacetals; 
silylene derivatives; 1,1,3,3-tetraisopropyl disiloXanylidene 
derivatives or N,O-acetals. 
10. A compound according to claim 1 having formula II 
formula II 
5 R R6 
H 0R7 
H 0R8 
N \O—W 
0 
R7 and R8 are independently selected from H or Pr; 
W, R5 and R6 are as de?ned in claim 1. 
11. A compound according to claim 1 having formula III 
Wherein 
formula III 
5 
wherein R7, R8, R9 and R10 are each independently selected 
from H or Pr; 
W and R5, R6 are as de?ned in claim 1. 
12. Acompound according to claim 10 Wherein there are 
at least 2 different protecting groups Pr on R5, R7, R8, R9 and 
R10. 
13. A compound according to claim 1 Which corresponds 
to any of the folloWing formulae A to L: 
A 
O 
OH 
N W \O/ 
O 
B 
O 
OH 
OH 
N W \O/ 
O 
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-continued 
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-continued 
I 
O 
HO OPr1 
HO OPrZ 
N W \O/ 
O 
J 
O 
Pr3O,,II‘ OPr1 
Pr40\\“ OPrZ 
N W \O/ 
O 
wherein W is as de?ned in claim 1; Pr1 to Pr5 are hydroXyl 
protecting groups Which can be independently the same or 
different on each hydroXyl and can optionally protect at the 
same time tWo hydroXyl groups, and Nu is a nucleophilic 
group; 
their diastereoisorners, enantiorners and mixtures thereof. 
US 2005/0261492 A1 
14. A compound according to claim 13 wherein Nu is 
selected from the group formed by hydrogen, cyano, sub 
stituted or unsubstituted alkyl, substituted or unsubstituted 
cycloalkyl, substituted or unsubstituted alkenyl, substituted 
or unsubstituted alkynyl, substituted or unsubstituted aryl, 
substituted or unsubstituted heterocyclyl. 
15. A process for the preparation of a compound accord 
ing to claim 1 Which comprises in any order one or more 
steps selected from the group consisting of: 
a) hydroXylation or dihydroXylation 
b) hydroXyl or carbonyl protection 
c) nucleophilic attack on the carbonyl group 
d) hydroXyl inversion applied to a compound of formula 
IV: 
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formula IV 
Wherein Z, Y and W are as de?ned in claim 1. 
16. A compound as de?ned in claim 8, Wherein Q is 
phenyl. 
